Professor  Chen MAO (毛琛博士)  
MD (AMU), PhD (SMU)

Research Assistant Professor                                                                                                                                                                                       


Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Office: Rm 413, 4/F, School of Public Health    

                                                                                     

depid_chen_mao150.jpg

Biography 
Dr. Chen Mao obtained doctorate in Epidemiology and Biostatistics from Southern Medical University in 2011. He joined the Chinese University of Hong Kong as a Research Assistant in Division of Epidemiology of the School of Public Health and Primary Care in August 2010. He was promoted to Research Assistant Professor in November 2012. Dr. Mao is awarded The Most Promising Young Researcher Award in the School of Public Health and Primary Care in 2012 and earned the Grant under the “Scheme to Encourage High Impact Publications” in the Chinese University of Hong Kong in 2014. Dr. Mao has strong experiences in systematic reviews and meta-analyses. He obtained 70-80 publications and several research grants in this field in recent 5 years.
Teaching Modules
  • EPID5001 Introduction to Epidemiology 
  • EPID5002 Epidemiology Study Designs
  • EPID5003 Analysis of Epidemiological Data
  • EPID5000 Introduction to Epidemiology and Biostatistics
  • EPID6001 Appraisal of the Methods of Epidemiological Studies
Postgraduate Supervision 
  • Jin-Qiu Yuan (Co-supervisor), PhD candidate in Epidemiology, Combination therapies for hypertension: a network meta-analysis (2013-2017)
  • Yue-Lun Zhang (Co-supervisor), PhD candidate in Epidemiology, Identifying the determinants of absolute effectiveness of anti-diabetic and cholesterol-lowering drugs for primary prevention of cardiovascular diseases (2014-2017) 
  • Xiao-Hong Fu (Co-supervisor), PhD candidate in Epidemiology, The association of ambient air pollution with daily mortality and years of life lost in Ningbo, China, 2009-2014: a time-series study (2014-2018)
Research Interests 
  • Evidence-based medicine and evidence-based healthcare
  • Systematic reviews and meta-analyses
  • Predictive biomarkers for cancer treatment
  • Comparative effectiveness researches            
Research Grants as the Principal Investigator 
 
  • HRMF12130721, The concordance of KRAS, BRAF, PIK3CA, and PTEN status between primary tumors and corresponding metastases in patients with colorectal cancer: a systematic review and meta-analysis, Health and Medical Research Fund, Food and Health Bureau, 2015.07.1-2016.06.30, HK$ 356,664.00

  • Transmission of Hepatitis B and C virus infection through body piercing:  a systematic review and meta-analysis, Zhejiang University, 2014.11.30-2015.03.31, RMB 85,000.00

  • HMRF11120971, The predictive biomarkers for EGFR tyrosine kinase inhibitors treatment in patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials, Health and Medical Research Fund, Food and Health Bureau, 2014.01.01-2014.12.31, HK$ 214,416.00

  • 4054090, Factors that influence the effectiveness of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: a systematic review and meta-regression, Direct Grant under the Scheme to Encourage High Impact Publications,, The Chinese University of Hong Kong, 2014.01.01-2014.12.31, HK$ 100,000.00
Selected Publications (*Corresponding Author)

Comparative effectiveness researches:       

  1. Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, Li P, Ye QL, Guo B, Mao C*, Ye DQ. Comparative effectiveness and safety of therapies for Helicobacter pylori: a systematic review and network meta-analysis. BMJ 2015; 351:h4052. 

  2. Yuan JQ, Mao C*, Wong SY, Yang ZY, Fu XH, Dai XY, Tang JL*. Comparative Effectiveness and Safety of Mono-drug Therapies for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine (Baltimore) 2015; 94(27):e974.

  3. Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, Qin X, Ren Z, Ding H, Chen Q, Mao C*, Tang J. Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis. Eur Urol 2013; 63(5):902-12.   

Predictive biomarkers for cancer treatment:

  1. Mao C, Yuan JQ, Yang ZY, Fu XH, Wu XY, Tang JL*. Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of non-small cell lung cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2015; 94(21):e775.

  2. Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY, Tang JL*. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep 2015; 5:8065.

  3. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C*, Tang JL. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis. Int J Cancer 2013; 133(8):1914-25.

  4. Mao C,Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL*. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 2013; 119(4):714-21.

  5. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Ann Oncol 2012; 23(6):1518-1525.

  6. Yang ZY, Shen WX, Hu XF, Zheng DY, Wu XY, Huang YF, Chen JZ, Mao C*, Tang JL. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: meta analysis. J Hematol Oncol 2012; 5(1):52.

  7. Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, Li J, Chen Q.KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010; 69(3):272-8.

  8. Qiu LX, Mao C,  Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies. Eur J Cancer 2010; 46(15):2781-2787.(Co-first authors)

     



The Cochrane Database of Systematic Reviews: 


  1. Mao C, Fu XH, Yuan JQ, Yang ZY, Chung VCH, Qin Y, Huang Y, Tam WWS, Kwong JSW, Xie W, Tang JL. Tong-xinluo capsule for patients with coronary heart disease after percutaneous coronary intervention. Cochrane Database Syst Rev 2015; 5: CD010237.

  2. Mao C, Fu XH, Yuan JQ, Yang ZY, Huang YF, Ye QL, Wu XY, Hu XF, Zhai ZM, Tang JL. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. Cochrane Database Syst Rev. 2015 Nov 6;11:CD010248

  3. Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL*. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev 2014; 11:CD009948.

  4. Mao C, Yang ZY，He BF, Liu S, Zhou JH, Qiu LX, Luo RC, Chen Q, Tang JL*. Toremifene versus tamoxifen for advanced breast cancer. Cochrane Database Syst Rev 2012; 7: CD008926.


Correspondence:  

  1. Yang ZY, Mao C, Tang JL. Apixaban versus Enoxaparin in Medically ⅡPatients. N Engl J Med 2012; 366:767-768.

  2. Huang YF, Mao C. Exposure to air pollutants and myocardial infarction risk. JAMA 2012; 307(22):2370.

  3. Yuan JQ, Mao C*, Tang JL. Prevalence of risk factors for non-communicable diseases in prison populations. Lancet 2012; 380(9849):1227.

  4. Mao C, Tang JL. KRAS genotypes and outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2011; 305(6):565.

  5. Yang ZY, Mao C, Tang JL. Bevacizumab and cancer treatment-related mortality. JAMA 2011; 305(22):2291-2292.

 

 


 

 

 
[ Back ]